Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2019 May 1;25(9):2940. doi: 10.1158/1078-0432.CCR-19-0731. No abstract available.

PMID:
31043388
2.
3.
4.

Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2019 Apr;18(4):869. doi: 10.1158/1535-7163.MCT-19-0151. No abstract available.

PMID:
30936413
5.

Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors.

Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS.

Cancer Res. 2019 Apr 1;79(7):1716. doi: 10.1158/0008-5472.CAN-19-0502. No abstract available.

PMID:
30936080
6.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.

Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K.

Cancer Immunol Res. 2019 Mar;7(3):414-427. doi: 10.1158/2326-6066.CIR-18-0126. Epub 2019 Jan 4.

PMID:
30610059
7.

Retraction of "Development of a Novel Class of Glucose Transporter Inhibitors".

Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS.

J Med Chem. 2018 Jun 14;61(11):5056. doi: 10.1021/acs.jmedchem.8b00708. Epub 2018 May 18. No abstract available.

8.

Retraction of "Development of Novel Adenosine Monophosphate-Activated Protein Kinase Activators".

Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS.

J Med Chem. 2018 Jun 14;61(11):5055. doi: 10.1021/acs.jmedchem.8b00707. Epub 2018 May 18. No abstract available.

9.

Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.

Huang HL, Wu HY, Chu PC, Lai IL, Huang PH, Kulp SK, Pan SL, Teng CM, Chen CS.

Oncogenesis. 2017 Jul 10;6(7):e359. doi: 10.1038/oncsis.2017.61.

10.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.

BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6.

11.

Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.

Chuang HC, Huang PH, Kulp SK, Chen CS.

Pharmacol Res. 2017 Mar;117:370-376. doi: 10.1016/j.phrs.2017.01.006. Epub 2017 Jan 8. Review.

PMID:
28077300
12.

Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.

Chu PC, Kulp SK, Bekaii-Saab T, Chen CS.

Small GTPases. 2018 Nov 2;9(6):452-456. doi: 10.1080/21541248.2016.1251383. Epub 2016 Dec 9.

13.

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.

Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH.

Neoplasia. 2016 Dec;18(12):765-774. doi: 10.1016/j.neo.2016.10.003. Epub 2016 Nov 25.

14.

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK.

Exp Toxicol Pathol. 2016 Oct;68(9):505-515. doi: 10.1016/j.etp.2016.08.001. Epub 2016 Aug 21.

15.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK.

AAPS J. 2016 May;18(3):737-45. doi: 10.1208/s12248-016-9876-3. Epub 2016 Mar 4.

16.

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, Shapiro CL, Chen CS.

Carcinogenesis. 2016 Apr;37(4):430-442. doi: 10.1093/carcin/bgw020. Epub 2016 Feb 19.

17.

Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.

Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS.

Oncotarget. 2016 Jan 12;7(2):1796-807. doi: 10.18632/oncotarget.6427.

18.

Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells.

Chu PC, Yang MC, Kulp SK, Salunke SB, Himmel LE, Fang CS, Jadhav AM, Shan YS, Lee CT, Lai MD, Shirley LA, Bekaii-Saab T, Chen CS.

Oncogene. 2016 Jul 28;35(30):3897-908. doi: 10.1038/onc.2015.458. Epub 2015 Nov 30.

PMID:
26616862
19.

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS.

J Natl Cancer Inst. 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. Print 2015 Dec.

20.

Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators.

Dokla EM, Fang CS, Lai PT, Kulp SK, Serya RA, Ismail NS, Abouzid KA, Chen CS.

ChemMedChem. 2015 Nov;10(11):1915-23. doi: 10.1002/cmdc.201500371. Epub 2015 Sep 9.

21.

Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS.

Neoplasia. 2015 Jun;17(6):497-508. doi: 10.1016/j.neo.2015.06.001.

23.

Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.

Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS.

J Med Chem. 2015 Mar 12;58(5):2290-8. doi: 10.1021/jm501751b. Epub 2015 Feb 27.

24.

Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent.

Lo JH, Kulp SK, Chen CS, Chiu HC.

Antimicrob Agents Chemother. 2014 Dec;58(12):7375-82. doi: 10.1128/AAC.03778-14. Epub 2014 Sep 29.

25.

AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.

Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS.

Cancer Res. 2014 Sep 1;74(17):4783-95. doi: 10.1158/0008-5472.CAN-14-0135. Epub 2014 Jul 3. Erratum in: Cancer Res. 2018 Jun 15;78(12 ):3401.

26.

Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.

Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS.

Carcinogenesis. 2014 Oct;35(10):2203-13. doi: 10.1093/carcin/bgu124. Epub 2014 May 30. Retraction in: Carcinogenesis. 2019 Apr 29;40(2):e16.

27.

Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.

Berman-Booty LD, Thomas-Ahner JM, Bolon B, Oglesbee MJ, Clinton SK, Kulp SK, Chen CS, La Perle KM.

Toxicol Pathol. 2015 Feb;43(2):186-97. doi: 10.1177/0192623314531351. Epub 2014 Apr 17.

28.

Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.

Chou CC, Salunke SB, Kulp SK, Chen CS.

J Cell Biochem. 2014 Apr;115(4):611-24. doi: 10.1002/jcb.24704. Review.

29.
30.

AMPK as a potential anticancer target - friend or foe?

Chuang HC, Chou CC, Kulp SK, Chen CS.

Curr Pharm Des. 2014;20(15):2607-18. Review.

31.

Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.

Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CS.

PLoS One. 2013 Jun 19;8(6):e67149. doi: 10.1371/journal.pone.0067149. Print 2013. Retraction in: PLoS One. 2018 Aug 9;13(8):e0202299.

32.

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MA.

Leukemia. 2013 Dec;27(12):2379-82. doi: 10.1038/leu.2013.147. Epub 2013 May 10. No abstract available.

33.

Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.

Yang YL, Huang PH, Chiu HC, Kulp SK, Chen CS, Kuo CJ, Chen HD, Chen CS.

Biochem Biophys Res Commun. 2013 May 24;435(1):107-12. doi: 10.1016/j.bbrc.2013.04.049. Epub 2013 Apr 23.

PMID:
23624506
34.

Vitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1.

Huang PH, Chuang HC, Chou CC, Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS.

Sci Signal. 2013 Mar 19;6(267):ra19. doi: 10.1126/scisignal.2003816.

35.

Zeranol induces deleterious effects on the testes and the prostate gland of mature rats.

Shidaifat F, Kulp SK, Lin YC.

Endocr Res. 2013;38(4):232-41. doi: 10.3109/07435800.2013.774410. Epub 2013 Mar 15.

PMID:
23496416
36.

Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.

Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, Clinton SK, Kulp SK, Chen CS.

Cancer Prev Res (Phila). 2013 Mar;6(3):232-41. doi: 10.1158/1940-6207.CAPR-12-0057. Epub 2012 Dec 28.

37.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

38.

The mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition.

Chu PC, Chuang HC, Kulp SK, Chen CS.

J Biol Chem. 2012 Dec 21;287(52):43639-50. doi: 10.1074/jbc.M112.393678. Epub 2012 Oct 31.

39.

Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.

Wei S, Chu PC, Chuang HC, Hung WC, Kulp SK, Chen CS.

PLoS One. 2012;7(10):e47298. doi: 10.1371/journal.pone.0047298. Epub 2012 Oct 12.

40.

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.

Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, Kulp SK, Teng LJ, Chen CS.

Bioorg Med Chem. 2012 Aug 1;20(15):4653-60. doi: 10.1016/j.bmc.2012.06.018. Epub 2012 Jun 15.

41.

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL.

Breast Cancer Res Treat. 2012 Jul;134(2):649-59. doi: 10.1007/s10549-012-2106-5. Epub 2012 Jun 8.

42.

Development of a novel class of glucose transporter inhibitors.

Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS.

J Med Chem. 2012 Apr 26;55(8):3827-36. doi: 10.1021/jm300015m. Epub 2012 Apr 10. Retraction in: J Med Chem. 2018 Jun 14;61(11):5056.

43.

Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma.

Lu YS, Chou CH, Tzen KY, Gao M, Cheng AL, Kulp SK, Cheng JC.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e181-9. doi: 10.1016/j.ijrobp.2011.12.022. Epub 2012 Feb 28.

PMID:
22381897
44.

Met interacts with EGFR and Ron in canine osteosarcoma.

McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA.

Vet Comp Oncol. 2013 Jun;11(2):124-39. doi: 10.1111/j.1476-5829.2011.00309.x. Epub 2011 Dec 8.

45.

A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice.

Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, Kulp SK.

Toxicol Pathol. 2012;40(1):5-17. doi: 10.1177/0192623311425062. Epub 2011 Oct 21. Review.

46.

Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS.

J Biol Chem. 2011 Nov 11;286(45):39247-58. doi: 10.1074/jbc.M111.264598. Epub 2011 Sep 14.

47.

Identification and characterization of a novel integrin-linked kinase inhibitor.

Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS.

J Med Chem. 2011 Sep 22;54(18):6364-74. doi: 10.1021/jm2007744. Epub 2011 Aug 24.

48.

Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells.

Li H, Piao L, Xu P, Ye W, Zhong S, Lin SH, Kulp SK, Mao Y, Cho Y, Lee LJ, Lee RJ, Lin YC.

Pharm Res. 2011 Dec;28(12):3256-64. doi: 10.1007/s11095-011-0498-2. Epub 2011 Jun 28.

49.

OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.

Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N.

Br J Haematol. 2011 Jun;153(5):623-33. doi: 10.1111/j.1365-2141.2010.08443.x. Epub 2011 Apr 7.

50.

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS.

Hepatology. 2011 Jun;53(6):1943-58. doi: 10.1002/hep.24293. Epub 2011 May 2.

Supplemental Content

Support Center